Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Basil S Lewis

Showing results (181-190 of 240) with videos related to

Pageof 24
Sort By:
European Journal of Heart Failure|March 3, 2022
Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fractionClara Saldarriaga, Dan Atar, Amanda Stebbins, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 24, 2019
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on StrokePatrick Sulzgruber, Sven Wassmann, Anne Grete Semb, et al.
European Heart Journal|September 22, 2019
Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1Patrick Sulzgruber, Sven Wassmann, Anne Grete Semb, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 7, 2024
Oral anticoagulation in patients with left ventricular thrombus: a systematic review and meta-analysisPaul M Haller, Niema Kazem, Stefan Agewall, et al.
JAMA Cardiology|April 30, 2020
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical TrialStephen D Wiviott, Robert P Giugliano, David A Morrow, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 6, 2021
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyMaria Lukács Krogager, Kristian Kragholm, Jesper Qvist Thomassen, et al.
The New England Journal of Medicine|September 1, 2009
Dabigatran versus warfarin in patients with atrial fibrillationStuart J Connolly, Michael D Ezekowitz, Salim Yusuf, et al.
Circulation|August 12, 2015
Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial"Benjamin M Scirica, Eugene Braunwald, Itamar Raz, et al.
Circulation|September 6, 2014
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trialBenjamin M Scirica, Eugene Braunwald, Itamar Raz, et al.
The Lancet. Diabetes & Endocrinology|September 21, 2017
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trialMarc S Sabatine, Lawrence A Leiter, Stephen D Wiviott, et al.
Pageof 24

Showing results (181-190 of 240) with videos related to

Sort By:
Pageof 24
European Journal of Heart Failure|March 3, 2022
Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fractionClara Saldarriaga, Dan Atar, Amanda Stebbins, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 24, 2019
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on StrokePatrick Sulzgruber, Sven Wassmann, Anne Grete Semb, et al.
European Heart Journal|September 22, 2019
Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1Patrick Sulzgruber, Sven Wassmann, Anne Grete Semb, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 7, 2024
Oral anticoagulation in patients with left ventricular thrombus: a systematic review and meta-analysisPaul M Haller, Niema Kazem, Stefan Agewall, et al.
JAMA Cardiology|April 30, 2020
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical TrialStephen D Wiviott, Robert P Giugliano, David A Morrow, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 6, 2021
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular PharmacotherapyMaria Lukács Krogager, Kristian Kragholm, Jesper Qvist Thomassen, et al.
The New England Journal of Medicine|September 1, 2009
Dabigatran versus warfarin in patients with atrial fibrillationStuart J Connolly, Michael D Ezekowitz, Salim Yusuf, et al.
Circulation|August 12, 2015
Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial"Benjamin M Scirica, Eugene Braunwald, Itamar Raz, et al.
Circulation|September 6, 2014
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trialBenjamin M Scirica, Eugene Braunwald, Itamar Raz, et al.
The Lancet. Diabetes & Endocrinology|September 21, 2017
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trialMarc S Sabatine, Lawrence A Leiter, Stephen D Wiviott, et al.
Pageof 24